EMBRACE the status quo,

When it comes to switching out bortezomib with the newer second-line proteasome inhibition carfilzomib in first-line combo therapy for multiple myeloma, we were right about only one thing: it increases toxicity. Unfortunately, among over 1000 patients, it failed to additionally improve either progression-free or overall survival, meeting futility at its second planned interim analysis. In other words, bortezomib + lenalidomide + dex remains standard initial therapy for most multiple myeloma. | Kumar, ASCO 2020